asbestos lawyers - Worthington & Caron, PC

Over $2.5 billion

obtained for mesothelioma patients & families

In The News

FDA Grants Fast Trak Status to Novel Therapy for Patients with Unresectable NF2-Deficient Malignant Pleural Mesothelioma

The U.S. Food and Drug Administration (FDA) has designated Fast Track status to a new therapeutic drug therapy for the treatment of malignant pleural mesothelioma (MPM) in patients with unresectable NF2-deficient tumors. The drug, IK-930, was granted Orphan Drug designation by the FDA earlier this year.

IK-930 was developed by Ikena Oncology, Inc. as a TEAD inhibitor which targets the Hippo signaling transduction pathway (HSTP) to disrupt gene and protein function in NF2-deficient tumor cancers to slow or halt cancer growth. It is estimated that 40% of mesothelioma cases are NF2-deficient.

IK-930 is to be administrated as an oral therapy as a monotherapy for MPM and is also being researched in Phase 1 clinical trials in the treatment of a variety of cancers with mutations in the HSTP including non-small cell lung cancer, soft tissue sarcoma and other cancers that are NF2 deficient or express YAP1 or TAZ gene fusions.

For more information on the Phase 1 Clinical Trial for IK-930 visit

Also, please visit Ikena Oncology’s June 22 press release and the National Library of Medicine.

Get Empowered

We put your medical and personal needs first and provide compassionate representation.

Please enter the captcha above: